ABSTRACT
Marburg virus (MARV) is the causal agent of MARV disease (MVD) (formerly known as Marburg hemorrhagic fever) in human and nonhuman primates, which was rst identied in 1967 during epidemics in Marburg and Frankfurt in Germany and Belgrade in the former Yugoslavia from importation of infected monkeys from Uganda [1,2]. Similar to the Ebola virus (EBOV) disease, MVD is a severe and highly fatal disease. Both MARV and EBOV are among the most virulent pathogens known to infect humans. Both diseases are rare, but have a capacity to cause dramatic outbreaks with high fatality. Despite signicant progress in drug development for MVD [3], there are no approved vaccines or postexposure treatment drugs available yet. The predominant treatment is general supportive therapy.
